130 related articles for article (PubMed ID: 19908230)
1. The effects of telomerase inhibition on prostate tumor-initiating cells.
Marian CO; Wright WE; Shay JW
Int J Cancer; 2010 Jul; 127(2):321-31. PubMed ID: 19908230
[TBL] [Abstract][Full Text] [Related]
2. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
[TBL] [Abstract][Full Text] [Related]
3. Prostate tumor-initiating cells: a new target for telomerase inhibition therapy?
Marian CO; Shay JW
Biochim Biophys Acta; 2009 Apr; 1792(4):289-96. PubMed ID: 19264126
[TBL] [Abstract][Full Text] [Related]
4. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C
Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190
[TBL] [Abstract][Full Text] [Related]
5. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Koziel JE; Herbert BS
Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
[TBL] [Abstract][Full Text] [Related]
6. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
7. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
Chen Z; Koeneman KS; Corey DR
Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
[TBL] [Abstract][Full Text] [Related]
8. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma.
Engelhardt M; Albanell J; Drullinsky P; Han W; Guillem J; Scher HI; Reuter V; Moore MA
Clin Cancer Res; 1997 Oct; 3(10):1849-57. PubMed ID: 9815573
[TBL] [Abstract][Full Text] [Related]
9. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
Hu Y; Bobb D; Lu Y; He J; Dome JS
Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
[TBL] [Abstract][Full Text] [Related]
10. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
[TBL] [Abstract][Full Text] [Related]
11. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology.
Meeker AK
Urol Oncol; 2006; 24(2):122-30. PubMed ID: 16520276
[TBL] [Abstract][Full Text] [Related]
12. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
[TBL] [Abstract][Full Text] [Related]
13. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition.
Castelo-Branco P; Zhang C; Lipman T; Fujitani M; Hansford L; Clarke I; Harley CB; Tressler R; Malkin D; Walker E; Kaplan DR; Dirks P; Tabori U
Clin Cancer Res; 2011 Jan; 17(1):111-21. PubMed ID: 21208905
[TBL] [Abstract][Full Text] [Related]
14. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
[TBL] [Abstract][Full Text] [Related]
15. Designed modulation of sex steroid signaling inhibits telomerase activity and proliferation of human prostate cancer cells.
Verma V; Sharma V; Singh V; Sharma S; Bishnoi AK; Chandra V; Maikhuri JP; Dwivedi A; Kumar A; Gupta G
Toxicol Appl Pharmacol; 2014 Oct; 280(2):323-34. PubMed ID: 25123791
[TBL] [Abstract][Full Text] [Related]
16. Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model.
Canales BK; Li Y; Thompson MG; Gleason JM; Chen Z; Malaeb B; Corey DR; Herbert BS; Shay JW; Koeneman KS
Urol Oncol; 2006; 24(2):141-51. PubMed ID: 16520278
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.
Shimada K; Anai S; Fujii T; Tanaka N; Fujimoto K; Konishi N
J Pathol; 2013 Dec; 231(4):495-504. PubMed ID: 24549646
[TBL] [Abstract][Full Text] [Related]
18. Indole-3-carbinol inhibits telomerase activity and gene expression in prostate cancer cell lines.
Adler S; Rashid G; Klein A
Anticancer Res; 2011 Nov; 31(11):3733-7. PubMed ID: 22110194
[TBL] [Abstract][Full Text] [Related]
19. Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.
Mender I; Senturk S; Ozgunes N; Akcali KC; Kletsas D; Gryaznov S; Can A; Shay JW; Dikmen ZG
Int J Oncol; 2013 May; 42(5):1709-15. PubMed ID: 23545855
[TBL] [Abstract][Full Text] [Related]
20. Telomere length and telomerase activity in bladder and prostate cancer cell lines.
Kageyama Y; Kamata S; Yonese J; Oshima H
Int J Urol; 1997 Jul; 4(4):407-10. PubMed ID: 9256332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
